Value of Serum Tumor Marker Isocitrate Dehydrogenase 1 in the Diagnosis of Lung Cancer.
10.3881/j.issn.1000-503X.11098
- Author:
Hao XIE
1
;
Yi Xiang KONG
2
;
Qiang ZHANG
1
Author Information
1. Department of Thoracic Surgery,Jishuitan Hospital,Beijing 100035,China.
2. Department of Breast Surgical Oncology,National Cancer Center/National Clinical Research Center for Cancer,Cancer Hospital,CAMS and PUMC,Beijing 100021,China.
- Publication Type:Journal Article
- Keywords:
auxiliary diagnosis;
isocitrate dehydrogenase 1;
lung cancer
- MeSH:
Biomarkers, Tumor;
Carcinoma, Non-Small-Cell Lung;
Humans;
Isocitrate Dehydrogenase;
blood;
Lung Neoplasms
- From:
Acta Academiae Medicinae Sinicae
2019;41(6):813-817
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the clinical value of serum tumor marker isocitrate dehydrogenase 1(IDH1)in the diagnosis of lung cancer. The general data were collected in lung cancer patients and non-lung cancer patients.The serum level of IDH1 was detected by enzyme-linked immunosorbent assay to evaluate its clinical significance in diagnosing lung cancer. The serum IDH1 level was significantly higher in lung cancer patients than in non-lung cancer patients [(7.12±6.98)ng/ml (2.09±1.83)ng/ml,=11.540,<0.001].The serum IDH1 level in patients with adenocarcinoma or squamous cell carcinoma was significantly higher than that in patients with small cell lung cancer [(7.91±7.26)ng/ml (2.76±2.27)ng/ml, =6.345,<0.001].The sensitivity of IDH1 in detecting lung cancer,stage Ⅰ/Ⅱ lung cancer,and stage Ⅲ/Ⅳ lung cancer was 47.4%,49.1%,and 46.3%,respectively. Serum IDH1 has high sensitivities and specificities in the diagnosis and differential diagnosis of non-small cell lung cancer(squamous cell carcinoma and adenocarcinoma)and small cell lung cancer as well as the auxiliary diagnosis of stage Ⅰ and Ⅱ lung cancer.It is a valuable marker for the auxiliary diagnosis of lung cancer.
